Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies

Bibliography

• HOHLFELD R, WIENDL H: The ups and downs of multiple sclerosis therapeutics. Ann. Neurol (2001) 49:281–284.
   PubMed Web of Science ®Google Scholar
• KIESEIER BC, HARTUNG H-P: Current disease-modifying therapies in multiple sclerosis. &min. Neurol (2003) (In press).
   Google Scholar
• ••A detailed overview on the current statusof disease-modifying therapies in MS.
   Google Scholar
• FILIPPI M, DOUSSET V, MCFARLAND HF, MILLER DH, GROSSMAN RI: Role of magnetic resonance imaging in the diagnosis and monitoring of multiple sclerosis: consensus report of the White Matter Study Group. I Magn. Reson. Imaging (2002) 15:499–504.
   PubMed Web of Science ®Google Scholar
• MCFARLAND HF, BARKHOF F, ANTEL J, MILLER DH: The role of MRI as a surrogate outcome measure in multiple sclerosis. Mult. Scler: (2002) 8:40–51.
   PubMed Web of Science ®Google Scholar
• MCDONALD WI, COMPSTON A, EDAN G et al: Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol (2001) 50:121–127.
   PubMed Web of Science ®Google Scholar
• WIENDL H, HOHLFELD R: Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs (2002) 16:183–200.
   PubMed Web of Science ®Google Scholar
• ••A detailed overview on recent MS trials that failed or have been interrupted.
   Google Scholar
• HOHLFELD R: Biotechnological agents for the immunotherapy of multiple sclerosis: principles, problems and perspectives. Brain (1997) 120:865–916.
   PubMed Web of Science ®Google Scholar
• •A thorough and in-depth review combining the immunology of MS and applicable or conceivable irnmunotherapeutic agents or approaches.
   Google Scholar
• WEILBACH FX, GOLD R: Disease modifying treatments for multiple sclerosis: what is on the horizon? CNS Drug (1999) 11:133–157.
   Web of Science ®Google Scholar
• WINGERCHUK DM, LUCCHINETTICE NOSEWORTHY JH: Multiple sclerosis: current pathophysiological concepts. Lab. Invest. (2001) 81:263–281.
   PubMed Web of Science ®Google Scholar
• NOSEWORTHY JH, LUCCHINETTI C, RODRIGUEZ M, WEINSHENKER BG: Multiple sclerosis. N Engl.' Med. (2000) 343:938–952.
   PubMed Web of Science ®Google Scholar
• •Thorough key article on MS clinics, aetiopathogenesis and current therapy.
   Google Scholar
• HEMMER B, ARCHELOS JJ, HARTUNG HP: New concepts in the immunopathogenesis of multiple sclerosis. Nat. Rev. Neurosci. (2002) 3:291–301.
   PubMed Web of Science ®Google Scholar
• •State of the art review summarising current concepts of MS immunopathogenesis.
   Google Scholar
• WEINSHENKER BG, BASS B, RICE GP et al.: The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain (1989) 112:133–146.
   Google Scholar
• SCHUMACHER FA, BEEVE GW, KIBLER RF et al: Problems of experimental trials of therapy in multiple sclerosis. Ann. NY Acad. Sci. (1965) 122:552–568.
   PubMed Web of Science ®Google Scholar
• LUBLIN FD, REINGOLD SC: Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology (1996) 46:907–911.
   Google Scholar
• LUCCHINETTI C, BRUCK W, RODRIGUEZ M, LASSMANN H: Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol (1996) 6:259–274.
   PubMed Web of Science ®Google Scholar
• LUCCHINETTI C, BRUCK W, PARISI J, SCHEITHAUER B, RODRIGUEZ M, LASSMANN H: Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol (2000) 47:707–717.
   PubMed Web of Science ®Google Scholar
• ••This article provides evidence for differentpatterns of MS lesion pathology supporting the hypothesis of heterogeneity in MS pathogenesis.
   Google Scholar
• LASSMANN H, BRUCK W, LUCCHINETTI C: Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Ma Med. (2001) 7:115–121.
   PubMed Web of Science ®Google Scholar
• LUCCHINETTI C, BRUCK W, NOSEWORTHY J: Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment. Can: Opin. Neurol (2001) 14:259–269.
   PubMed Web of Science ®Google Scholar
• STEINMAN L: Multiple sclerosis: a two-stage disease. Nat. bronunol (2001) 2:762–764.
   PubMed Web of Science ®Google Scholar
• BENOIST C, MATHIS D: Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry? Nat. Inonunol. (2001) 2:797–801.
   Google Scholar
• LANG HL, JACOBSEN H, IKEMIZU S et al.: A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat. bronunol (2002) 3:940–943.
   PubMed Web of Science ®Google Scholar
• ARCHELOS JJ, HARTUNG HP: Pathogenetic role of autoantibodies in neurological diseases. Trends NeuroscL (2000) 23:317–327.
   PubMed Web of Science ®Google Scholar
• •A good summary on the potential pathogenetic role of hurnoral mechanisms in MS and other neurological diseases.
   Google Scholar
• BABBE H, ROERS A, WAISMAN A et al: Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. Exp. Med. (2000) 192:393–404.
   PubMed Web of Science ®Google Scholar
• •Article showing that CD8+ T cells in MS lesions are clonally expanded.
   Google Scholar
• TRAPP BD, RANSOHOFF R, RUDICK R: Axonal pathology in multiple sclerosis: relationship to neurologic disability. Carr: Opin. Neurol (1999) 12:295–302.
   PubMed Web of Science ®Google Scholar
• BJARTMAR C, TRAPP BD: Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Carr. Opin. Neurol (2001) 14:271–278.
   PubMed Web of Science ®Google Scholar
• •Overview on data concerning the occurence and functional role of axonal degeneration in MS.
   Google Scholar
• ZIPP F, KRAMMER PH, WELLER M: Immune (dys)regulation in multiple sclerosis: role of the CD95-CD95 ligand system. Innnunol. Today (1999) 20:550–554.
   PubMedGoogle Scholar
• GOODIN DS, FROHMAN EM, GARMANY GP Jr et al.: Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology (2002) 58:169–178.
   Google Scholar
• ••Excellent compilation of evidence fromclinical studies and accompanying research data on disease-modifying therapies in MS.
   Google Scholar
• IFN(3 MULTIPLE SCLEROSIS STUDY GROUP: Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double- blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology (1993) 43:655–661.
   Google Scholar
• IFNI3 MULTIPLE SCLEROSIS STUDY GROUP: Interferon beta-lb in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNI3 Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology(1995) 45:1277–1285.
   Google Scholar
• JACOBS LD, COOKFAIR DL, RUDICK RA et al: Intramuscular interferon beta-la for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol (1996) 39:285–294.
   Google Scholar
• PRISMS STUDY GROUP: Randomized, double-blind, placebo-controlled study of interferon-beta 1a in relapsing/remitting multiple sclerosis. Lancet (1998) 352:1498–1504.
   PubMed Web of Science ®Google Scholar
• THE ONCE WEEKLY INTERFERON FOR MS STUDY GROUP: Evidence of interferon beta-la dose response in relapsing-remitting MS: the MIMS Study. Neurology (1999) 53:679–686.
   PubMed Web of Science ®Google Scholar
• PRISMS STUDY GROUP: PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology (2001) 56: 1628-1636.
   Google Scholar
• JOHNSON KP, BROOKS BR, COHEN JA et al.: Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a Phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology (1995) 45:1268–1276.
   Google Scholar
• JOHNSON KP, BROOKS BR, COHEN JA et al.: Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology (1998) 50:701–708.
   Google Scholar
• JOHNSON KP, BROOKS BR, FORD CC et al.: Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult. Sclec (2000) 6:255–266.
   Google Scholar
• COMI G, FILIPPI M, WOLINSKY JS: European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/ Canadian Glatiramer Acetate Study Group. Ann. Neurol (2001) 49:290–297.
   Google Scholar
• JACOBS LD, BECK RW, SIMON JH et al.: Intramuscular interferon beta-la therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl. I Med. (2000) 343:898–904.
   PubMed Web of Science ®Google Scholar
• COMI G, FILIPPI M, BARKHOF F et al: Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet (2001) 357:1576–1582.
   PubMed Web of Science ®Google Scholar
• EUROPEAN STUDY GROUP ON INTERFERON BETA-1B IN SECONDARY PROGRESSIVE MS: Placebo-controlled multicentre randomised trial of interferon beta-lb in treatment of secondary progressive multiple sclerosis. Lancet (1998) 352:1491–1497.
   PubMed Web of Science ®Google Scholar
• KAPPOS L, POLMAN C, POZZILLI C, THOMPSON A, BECKMANN K, DAHLKE F: Final analysis of the European multicenter trial on IFNbeta-lb in secondary-progressive MS. Neurology (2001) 57:1969–1975.
   PubMed Web of Science ®Google Scholar
• GOODKIN DE, NORTH AMERICAN SPMS STUDY GROUP: The North American Study of interferon beta-lb in secondary progressive multiple sclerosis. 52nd Annual Meeting of the American Academy of Neurology San Diego, CA, USA (2000) (Abstract LBN.002).
   Google Scholar
• SPECTRIMS STUDY GROUP: Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results. Neurology (2001) 56:1496–1504.
   PubMed Web of Science ®Google Scholar
• LI DK, ZHAO GJ, PATY DW: Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology (2001) 56:1505–1513.
   PubMed Web of Science ®Google Scholar
• COHEN JA, GOODMAN AD, HEIDENREICH FR: Results of IMPACT, a Phase III trial of interferon beta-1a in secondary progressive MS. Neurology (2001) 56:A148–A149.
   Web of Science ®Google Scholar
• CHAMPS STUDY GROUP: MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group. Neurology(2002) 59:998–1005.
   PubMed Web of Science ®Google Scholar
• BECK RW, CHANDLER DL, COLE SR et al.: Interferon beta-la for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann. Neurol (2002) 51:481–490.
   PubMed Web of Science ®Google Scholar
• POSER CM, PATY DW, SCHEINBERG L et al.: New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol (1983) 13:227–231.
   PubMed Web of Science ®Google Scholar
• COHEN JA, CUTTER GR, FISCHER JS et al.: Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology (2002) 59:679–687.
   PubMed Web of Science ®Google Scholar
• KURTZKE JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology(1983) 33:1444–1452.
   PubMed Web of Science ®Google Scholar
• CUTTER GR, BAIER ML, RUDICK RA et al.: Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brad) (1999) 122:871–882.
   PubMed Web of Science ®Google Scholar
• FISHER E, RUDICK RA, SIMON JH et al.: Eight-year follow-up study of brain atrophy in patients with MS. Neurology (2002) 59:1412–1420.
   PubMed Web of Science ®Google Scholar
• LEARY SM, MILLER DH, STEVENSON VL, BREX PA, CHARD DT, THOMPSON AJ: Interferon beta-la in primary progressive MS: an exploratory, randomized, controlled trial. Neurology (2003) 60:44–51.
   PubMed Web of Science ®Google Scholar
• THOMPSON AJ, MONTALBAN X, BARKHOF F et al.: Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann. Neurol (2000) 47:831–835.
   PubMed Web of Science ®Google Scholar
• MCDONNELL GV, HAWKINS SA: Primary progressive multiple sclerosis: increasing clarity but many unanswered questions. Neurol Sci. (2002) 199:1–15.
   Web of Science ®Google Scholar
• BITSCH A, BRUCK W: Differentiation of multiple sclerosis subtypes: implications for treatment. CNS Drugs (2002) 16:405–418.
   PubMed Web of Science ®Google Scholar
• WOLINSKY JS, COMI G, FILIPPI M, LADKANI D, KADOSH S, SHIFRONI G: Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained. Neurology (2002) 59:1284–1286.
   PubMed Web of Science ®Google Scholar
• ROVARIS M, CODELLA M, MOIOLA L et al.: Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses. Neurology(2002) 59:1429–1432.
   PubMed Web of Science ®Google Scholar
• DURELLI L, VERDUN E, BARBERO P et al.: Every-other-day interferon beta- lb versus once-weekly interferon beta-la for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet (2002) 359:1453–1460.
   PubMed Web of Science ®Google Scholar
• PANITCH H, GOODIN DS, FRANCIS G et al.: Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology (2002) 59:1496–1506.
   PubMed Web of Science ®Google Scholar
• ••The two trials in [59] and [60], and theaccompanying editorials [61,62], highlight the complexities of head-to-head comparison trials of active agents.
   Google Scholar
• LUBLIN FD: When marketing and science intersect: do patients with MS benefit? Neurology (2002) 59:1480–1481.
   PubMed Web of Science ®Google Scholar
• KIEBURTZ K, MCDERMOTT M: Needed in MS: evidence, not EVIDENCE. Neurology (2002) 59:1482–1483.
   PubMed Web of Science ®Google Scholar
• RIO J, NOS C, TINTORE M et al.: Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials. Ann. Neurol (2002) 52:400–406.
   PubMed Web of Science ®Google Scholar
• NOSEWORTHY JH, O'BRIEN P, ERICKSON BJ et al: The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis. Neurology (1998) 51:1342–1352.
   PubMed Web of Science ®Google Scholar
• CLANET M, RADUE EW, KAPPOS L et al.: A randomized, double-blind, dose-comparison study of weekly interferon beta-la in relapsing MS. Neurology(2002) 59:1507–1517.
   PubMed Web of Science ®Google Scholar
• FLECHTER S, VARDI J, POLLAK L, RABEY JM: Comparison of glatiramer acetate (Copaxone) and interferon beta-lb (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up. Neurol Sci. (2002) 197:51–55.
   Web of Science ®Google Scholar
• HARTUNG HP, GONSETTE R, KONIG N et al.: Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet (2002) 360:2018–2025.
   PubMed Web of Science ®Google Scholar
• VAN DE WYNGAERT FA, BEGUIN C, D'HOOGHE MB et al.: A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis. Acta Neurol Belg. (2001) 101:210–216.
   Google Scholar
• ••The above two trials [67,68] (together with[69,70,71]) provide additional evidence that mitoxantrone reduces active inflammatory pathology in active and progressive forms of MS.
   Google Scholar
• BASTIANELLO S, POZZILLI C, D'ANDREA F et al.: A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. Can. Neurol Sci. (1994) 21:266–270.
   Google Scholar
• MILLEFIORINI E, GASPERINI C, POZZILLI C et al.: Randomized placebo-controlled trial of mitoxantrone in relapsing- remitting multiple sclerosis: 24-month clinical and MRI outcome. Neurol (1997) 244:153–159.
   Web of Science ®Google Scholar
• EDAN G, MILLER D, CLANET M et al.:Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. Neurol Neurosurg. Psychiatry (1997) 62:112–118.
   PubMed Web of Science ®Google Scholar
• STROTMANN JM, SPINDLER M, WEILBACH FX, GOLD R, ERTL G, VOELKER W: Myocardial function in patients with multiple sclerosis treated with low-dose mitoxantrone. Am. Cardiol (2002) 89:1222–1225.
   PubMed Web of Science ®Google Scholar
• FAZEKAS F, DEISENHAMMER F, STRASSER-FUCHS S, NAHLER G, MAMOLI B: Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet (1997) 349:589–593.
   PubMed Web of Science ®Google Scholar
• ACHIRON A, GABBAY U, GILAD R et al.: Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology (1998) 50:398–402.
   PubMed Web of Science ®Google Scholar
• SORENSEN PS, WANSCHER B, JENSEN CV et al.: Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology (1998) 50:1273–1281.
   PubMed Web of Science ®Google Scholar
• LEWANSKA M, SIGER-ZAJDEL M, SELMAJ K: No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. Ear.' Neurol (2002) 9:565–572.
   PubMed Web of Science ®Google Scholar
• SORENSEN PS, FAZEKAS F, LEE M: Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Eui: Neurol (2002) 9:557–563.
   PubMed Web of Science ®Google Scholar
• SOELBERG-SOERENSEN P: ESIMS. European Charcot Foundation, Venice, Italy (2001).
   Google Scholar
• YUDKIN PL, ELLISON GW, GHEZZI A et al.: Overview of azathioprine treatment in multiple sclerosis. Lancet (1991) 338:1051–1055.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ 0, GUERRERO M, MAYORGA C et al.: Combination therapy with interferon beta-lb and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study. Neurol (2002) 249:1058–1062.
   Google Scholar
• FRAUWIRTH KA, THOMPSON CB: Activation and inhibition of lymphocytes by costimulation. Clin. Invest. (2002) 109:295–299.
   Google Scholar
• KOBATA T, AZUMA M, YAGITA H, OKUMURA K: Role of costimulatory molecules in autoimmunity. Rev Immunogenet. (2000) 2:74–80.
   PubMedGoogle Scholar
• CARRENO BM, COLLINS M: The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Ann. Rev Immunol (2002) 20:29–53.
   PubMed Web of Science ®Google Scholar
• RACKE MK, STUART RW: Targeting Tcell costimulation in autoimmune disease. Expert Opin. Ther. Targets (2002) 6:275–289.
   PubMedGoogle Scholar
• SHARPE AH, FREEMAN GJ: The B7-CD28 superfamily. Nat. Rev Immunol (2002) 2:116–126.
   PubMed Web of Science ®Google Scholar
• SALOMON B, BLUESTONE JA: Complexities of CD28/B7:CTLA-4 costimulatory pathways in autoimmunity and transplantation. Ann. Rev Immunol (2001) 19:225–252.
   PubMed Web of Science ®Google Scholar
• ANDERSON DE, SHARPE AH, HAFLER DA: The B7-CD28/CTLA-4 costimulatory pathways in autoimmune disease of the central nervous system. Curc Opin. Immunol (1999) 11:677–683.
   PubMed Web of Science ®Google Scholar
• RACKE MK, RATTS RB, ARREDONDO L, PERRIN PJ, LOVETT-RACKE A: The role of costimulation in autoimmune demyelination. Neuroimmunol (2000) 107:205–215.
   PubMed Web of Science ®Google Scholar
• LOVETT-RACKE AE, TROTTER JL, LAUBER J, PERRIN PJ, JUNE CH, RACKE MK: Decreased dependence of myelin basic protein-reactive T cells on CD28- mediated costimulation in multiple sclerosis patients. A marker of activated/ memory T cells. Clin. Invest. (1998) 101:725–730.
   PubMed Web of Science ®Google Scholar
• ANDERSON DE, BIEGANOWSKA KD, BAR-OR A et al.: Paradoxical inhibition of T-cell function in response to CTLA-4 blockade; heterogeneity within the human T-cell population. Nat. Med. (2000) 6:211–214.
   PubMed Web of Science ®Google Scholar
• SCHOLZ C, PATTON KT, ANDERSON DE, FREEMAN GJ, HAFLER DA: Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 costimulation. .1 Immunol (1998) 160:1532–1538.
   PubMed Web of Science ®Google Scholar
• MARKOVIC-PLESE S, CORTESE I, WANDINGER KP, MCFARLAND HF, MARTIN R: CD4+CD28-costimulation-independent T cells in multiple sclerosis. Clin. Invest. (2001) 108:1185–1194.
   Google Scholar
• MAURER M, LOSERTH S, KOLB-MAURER A et al.: A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1 +49) altersT-cell activation. Immunogenetics (2002) 54:1–8.
   PubMed Web of Science ®Google Scholar
• KANTARCI OH, HEBRINK DD, ACHENBACH SJ et al.: CTLA4 is associated with susceptibility to multiple sclerosis.' Neuroimmunol (2003) 134:133–141.
   PubMed Web of Science ®Google Scholar
• LINSLEY PS, BRADY W, URNES M, GROSMAIRE LS, DAMLE NK, LEDBETTER JA: CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. (1991) 174:561–569.
   PubMed Web of Science ®Google Scholar
• COLES AJ, WING MG, MOLYNEUX P et al.: Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann. Neurol (1999) 46:296–304.
   PubMed Web of Science ®Google Scholar
• COLES AJ, WING M, SMITH S et al.: Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet (1999) 354:1691–1695.
   PubMed Web of Science ®Google Scholar
• HUSTON JS, GEORGE AJ: Engineered antibodies take center stage. Hum. Antibodies (2001) 10:127–142.
   PubMedGoogle Scholar
• WEINBERG AD, BOURDETTE DN, SULLIVAN TJ et at Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis. Nat. Med. (1996) 2:183–189.
   PubMed Web of Science ®Google Scholar
• SPERLING Al: ICOS costimulation: is it the key to selective immunotherapy? Clin. Immunol (2001) 100:261–262.
   Web of Science ®Google Scholar
• MEDAER R, STINISSEN P, TRUYEN L, RAUS J, ZHANG J: Depletion of myelin-basic-protein autoreactive T cells by T-cell vaccination: pilot trial in multiple sclerosis. Lancet (1995) 346:807–808.
   PubMed Web of Science ®Google Scholar
• VANDENBARK AA, CHOU YK, WHITHAM R et al: Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial. Nat. Med. (1996) 2:1109–1115.
   PubMed Web of Science ®Google Scholar
• KILLESTEIN J, OLSSON T, WALLSTROM E et at Antibody-mediated suppression of Vbeta5.2/5.3(+) T cells in multiple sclerosis: results from an MRI-monitored Phase II clinical trial. Ann. Neurol (2002) 51:467–474.
   Google Scholar
• OLSSON T, EDENIUS C, FERM M et al.: Depletion of Vbeta5.2/5.3 T cells with a humanized antibody in patients with multiple sclerosis. Eucf Neurol (2002) 9:153–164.
   Google Scholar
• VAN DER AA A, HELLINGS N, MEDAER R et al.: T cell vaccination in multiple sclerosis patients with autologous CSF-derived activated T cells: results from a pilot study. Clin. Exp. Immunol (2003) 131:155–168.
   Google Scholar
• BIELEKOVA B, GOODWIN B, RICHERT N et al.: Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a Phase II clinical trial with an altered peptide ligand. Nat. Med. (2000) 6:1167–1175.
   PubMed Web of Science ®Google Scholar
• •This paper and [107] report the largely disappointing results of clinical trials with an APL related to MBP.
   Google Scholar
• KAPPOS L, COMI G, PANITCH H et al: Induction of a non-encephalitogenic Type 2 T-helper cell autoimmune response in multiple Sclerosis after administration of an altered peptide ligand in a placebo controlled, randomized Phase II trial. Nat. Med. (2000) 6:1176–1182.
   PubMed Web of Science ®Google Scholar
• ARCHELOS JJ, STORCH MK, HARTUNG HP: The role of B cells and autoantibodies in multiple sclerosis. Ann. Neurol (2000) 47:694–706.
   PubMed Web of Science ®Google Scholar
• LUCCHINETTI C, MANDLER RN, MCGAVERN D et al: A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain (2002) 125:1450–1461.
   PubMed Web of Science ®Google Scholar
• BRUCK W, NEUBERT K, BERGER T, WEBER JR: Clinical, radiological, immunological and pathological findings in inflammatory CNS demyelination-possible markers for an antibody-mediated process. Mult. Scler. (2001) 7:173–177.
   PubMed Web of Science ®Google Scholar
• GOLD R, LININGTON C: Devic's disease: bridging the gap between laboratory and clinic. Brain (2002) 125:1425–1427.
   PubMed Web of Science ®Google Scholar
• WEINSHENKER BG, O'BRIEN PC, PETTERSON TM et al.: A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann. Neurol (1999) 46:878–886.
   Google Scholar
• KEEGAN M, PINEDA AA, MCCLELLAND RL, DARBY CH, RODRIGUEZ M, WEINSHENKER BG: Plasma exchange for severe attacks of CNS demyelination: Predictors of response. Neurology(2002) 58:143–146.
   PubMed Web of Science ®Google Scholar
• MAO-DRAAYER Y, BRAFF S, PENDLEBURY W, PANITCH H: Treatment of steroid-unresponsive tumefactive demyelinating disease with plasma exchange. Neurology (2002) 59:1074–1077.
   PubMed Web of Science ®Google Scholar
• GRILLO-LOPEZ AJ, HEDRICK E, RASHFORD M, BENYUNES M: Ritwdmab: ongoing and future clinical development. Semin. Oncol (2002) 29:105–112.
   PubMed Web of Science ®Google Scholar
• ARCHELOS JJ, PREVITALI SC, HARTUNG HP: The role of integrins in immune-mediated diseases of the nervous system. Trends Neurosci. (1999) 22:30–38.
   PubMed Web of Science ®Google Scholar
• TUBRIDY N, BEHAN PO, CAPILDEO R et al.: The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology (1999) 53:466–472.
   PubMed Web of Science ®Google Scholar
• MILLER DH, KHAN OA, SHEREMATA WA et al.: A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl. J. Med. (2003) 348:15–23.
   PubMed Web of Science ®Google Scholar
• ••This article demonstrates efficacy ofblocking 0G4 integrins with a humanised antibody in reducing MRI activity in MS (see also accompanying editorial reference [119]).
   Google Scholar
• VON ANDRIAN UH, ENGELHARDT B: Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl. J. Med. (2003) 348:68–72.
   PubMed Web of Science ®Google Scholar
• BAGGIOLINI M: Chemokines and leukocyte traffic. Nature (1998) 392:565–568.
   PubMed Web of Science ®Google Scholar
• SORENSEN TL, TANI M, JEMSEM J: Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J. Clio. Invest. (1999) 103:807–815.
   PubMed Web of Science ®Google Scholar
• •This article provides evidence for the role of chemokines and their specific receptors in the pathogenesis of MS.
   Google Scholar
• RANSOHOFF RIVI: Mechanisms of inflammation in MS tissue: adhesion molecules and chemokines. Neuroimmunol. (1999) 98:57–68.
   Google Scholar
• GLABINSK AR, RANSOHOFF RM: Targeting the chemokine system for multiple sclerosis treatment. Curr: Opin. Investig. Drugs (2001) 2:1712–1719.
   PubMedGoogle Scholar
• ELICES MJ: BX-471 Berlex. Carr. Opin. Investig. Drugs (2002) 3:865–869.
   PubMedGoogle Scholar
• HARTUNG HP, KIESEIER BC: The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. Neuroimmunol. (2000) 107:140–147.
   PubMed Web of Science ®Google Scholar
• YONG VW, POWER C, FORSYTH P, EDWARDS DR: Metalloproteinases in biology and pathology of the nervous system. Nat. Rev Neurosci. (2001) 2:502–511.
   PubMed Web of Science ®Google Scholar
• •In-depth review on the role of metalloproteinases in nervous system physiology and pathology.
   Google Scholar
• CLEMENTS JM, COSSINS JA, WELLS GMA et al.: Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumor necrosis factor-a inhibitor. Neuroimmunol. (1997) 74:85–94.
   PubMed Web of Science ®Google Scholar
• KIESEIER BC, KIEFER R, CLEMENTS JM et al.: Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain (1998) 121:159–166.
   PubMed Web of Science ®Google Scholar
• MAEDA A, SOBEL RA: Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. Neuropathol Exp. Neurol (1996) 55:300–309.
   PubMed Web of Science ®Google Scholar
• LINDBERG RL, DE GROOT CJ, MONTAGNE L et al.: The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. Brain (2001) 124:1743–1753.
   PubMed Web of Science ®Google Scholar
• KIESEIER BC, SEIFERT T, GIOVANNONI G, HARTUNG HP: Matrix metalloproteinases in inflammatory demyelination: targets for treatment. Neurology (1999) 53:20–25.
   PubMed Web of Science ®Google Scholar
• PAEMEN L, MARTENS E, NORGA K et al.: The gelatinase inhibitory activity of tetracyclines and chemically modified tetracycline analogues as measured by a novel microtiter assay for inhibitors. Biochem. Pharmacol. (1996) 52:105–111.
   PubMed Web of Science ®Google Scholar
• BRUNDULA V, REWCASTLE NB, METZ LM, BERNARD CC, YONG VW: Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain (2002) 12:1297–1308.
   Google Scholar
• POPOVIC N, SCHUBART A, GOETZ BD, ZHANG SC, LININGTON C, DUNCAN ID: Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann. Neurol (2002) 51:215–223.
   PubMed Web of Science ®Google Scholar
• THOENEN H, SENDTNER M: Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches. Nat. Neurosci. (2002) 5(Suppl.):1046–1050.
   Google Scholar
• BOTHWELL M: Functional interactions of neurotrophins and neurotrophin receptors. Ann. Rev. Neurosci. (1995) 18:223–253.
   PubMed Web of Science ®Google Scholar
• VILLOSLADA P, HAUSER SL, BARTKE I et al.: Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell Type 1 and 2 cytokines within the central nervous system. I Exp. Med. (2000) 191:1799–1806.
   PubMed Web of Science ®Google Scholar
• KERSCHENSTEINER M, STADELMANN C, DECHANT G, WEKERLE H, HOHLFELD R: Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann. Neural. (2003) 53:292–304.
   PubMed Web of Science ®Google Scholar
• ••This article provides an excellent overviewon existing data concerning the function and role of neurotrophins in neurological disease with special respect to its potential implications for MS pathogenesis and therapy.
   Google Scholar
• RANSOHOFF RM, HOWE CL, RODRIGUEZ M: Growth factor treatment of demyelinating disease: at last, a leap into the light. Trends bronunol. (2002) 23:512–516.
   PubMed Web of Science ®Google Scholar
• KERSCHENSTEINER M, GALLMEIER E, BEHRENS L et al: Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? Exp. Med. (1999) 189:865–870.
   Web of Science ®Google Scholar
• STADELMANN C, KERSCHENSTEINER M, MISGELD T, BRUCK W, HOHLFELD R, LASSMANN H: BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain (2002) 125:75–85.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ M, MOALEM G, LEIBOWITZ-AMIT R, COHEN IR: Innate and adaptive immune responses can be beneficial for CNS repair. Trends Neurosci. (1999) 22:295–299.
   PubMed Web of Science ®Google Scholar
• LINKER RA, MAURER M, GAUPP S et al.: CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat. Med. (2002) 8:620–624.
   PubMed Web of Science ®Google Scholar
• BUTZKUEVEN H, ZHANG JG, SOILU-HANNINEN M et al.: LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival. Nat. Med. (2002) 8:613–619.
   PubMed Web of Science ®Google Scholar
• FRANK JA, RICHERT N, LEWIS B et al.: A pilot study of recombinant insulin-like growth factor-1 in seven multiple sclerosis patients. Mult. Sclec (2002) 8:24–29.
   PubMed Web of Science ®Google Scholar
• KALKERS NF, BARKHOF F, BERGERS E, VAN SCHIJNDEL R, POLMAN CH: The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Mult. Scler. (2002) 8:532–533.
   PubMed Web of Science ®Google Scholar
• CHANG A, TOURTELLOTTE WW, RUDICK R, TRAPP BD: Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl. J. Med. (2002) 346:165–173.
   PubMed Web of Science ®Google Scholar
• STANGEL M, HARTUNG HP: Remyelinating strategies for the treatment of multiple sclerosis. Frog. Neurobiol (2002) 68:361–376.
   Google Scholar
• BLAKEMORE WE FRANKLIN RJ: Transplantation options for therapeutic central nervous system remyelination. Cell Transplant. (2000) 9:289–294.
   PubMed Web of Science ®Google Scholar
• HOHLFELD R: How promising is hematopoietic stem cell transplantation in multiple sclerosis?' Neurol (2002) 249:1147–1149.
   PubMed Web of Science ®Google Scholar
• FASSAS A, PASSWEG JR, ANAGNOSTOPOULOS A et al: Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study.' Neurol (2002) 249:1088–1097.
   Web of Science ®Google Scholar
• MAURER M, RIECKMANN P: What is the potential of combination therapy in MS. BioDrugs (2000) .
   Google Scholar
• ELIT L: CCI-779 Wyeth. Carr: Opin. Investig. Drugs (2002) 3:1249–1253.
   Google Scholar
• AHRENS N, SALAMA A, HAAS J: Mycophenolate-mofetil in the treatment of refractory multiple sclerosis. Neurol (2001) 248:713–714.
   Web of Science ®Google Scholar
• BEGGIOLIN G, CRIPPA L, MENTA E et al.: Bbr 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity. Tuinori (2001) 87:407–416.
   Google Scholar
• CHOU KM, KRAPCHO AP, HORN D, HACKER M: Characterization of anthracenediones and their photoaffinity analogs. Biochern. Pliarinacol (2002) 63:1143–1147.
   PubMed Web of Science ®Google Scholar
• BRUNMARK C, RUNSTROM A, OHLSSON L et al.: The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis.' Neurolininunol. (2002) 130:163–172.
   PubMed Web of Science ®Google Scholar
• DYKE HJ, MONTANA JG: Update on the therapeutic potential of PDE4 inhibitors. Expert Opin. Investig. Drugs (2002) 11(1):1–13.
   PubMed Web of Science ®Google Scholar
• BIELEKOVA B, LINCOLN A, MCFARLAND H, MARTIN R: Therapeutic potential 4 and -3 inhibitors in autoimmune diseases. 164:1117-1124.
   Google Scholar
• SOMMER N, LOSCHMANN PA, NORTHOFF GH et al: The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat. Med. (1995) 1:244–248.
   PubMed Web of Science ®Google Scholar
• JUNG S, ZIELASEK J, KOLLNER G, DONHAUSER T, TOYKA K, HARTUNG HP: Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats. Neuroinanunol. (1996) 68:1–11.
   PubMed Web of Science ®Google Scholar
• DINTER H, TSE J, HALKS-MILLER M: The Type IV phosphodiesterase specific inhibitor mesopram inhibits experimental autoimmune encephalomyelitis in rodents. Neuroinanunol. (2000) 108:136–146.
   PubMed Web of Science ®Google Scholar
• KWAK B, MULHAUPT F, MYIT S, MACH F: Statins as a newly recognized type of immunomodulator. Nat. Med. (2000) 6:1399–1402.
   PubMed Web of Science ®Google Scholar
• STANISLAUS R, SINGH AK, SINGH I: Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis. Neurosci. Res. (2001) 66:155–162.
   Web of Science ®Google Scholar
• YOUSSEF S, STUVE 0, PATARROYO IC: The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature (2002) 420:78–84.
   PubMed Web of Science ®Google Scholar
• NEUHAUS 0, STRASSER-FUCHS S, FAZEKAS F: Statins as immunomodulators: comparison with interferon-beta lb in MS. Neurology(2002) 59:990–997.
   PubMed Web of Science ®Google Scholar
• WEITZ-SCHMIDT G, WELZENBACH K, BRINKMANN V et al.: Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. (2001) 7:687–692.
   PubMed Web of Science ®Google Scholar
• BEBO BF Jr, FYFE-JOHNSON A, ADLARD K, BEAM AG, VANDENBARK AA, OFFNER H: Low-dose estrogen therapy ameliorates experimental autoimmune encephalomyelitis in two different inbred mouse strains. Inanunol. (2001) 166:2080–2089.
   Google Scholar
• SICOTTE NL, LIVA SM, KLUTCH R et al.: Treatment of multiple sclerosis with of phosphodiesterase-Thl-mediated bronunol. (2000) the pregnancy hormone estriol. Ann. Neurol (2002) 52:421–428.
   Google Scholar
• SCOTT GS, SPITSIN SV, KEAN RB, MIKHEEVA T, KOPROWSKI H, HOOPER DC: Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. Proc. Natl. Acad. Sci. USA (2002) 99:16303–16308.
   PubMed Web of Science ®Google Scholar
• SWANBORG RH, WHITTUM-HUDSON JA, HUDSON AP: Human herpesvirus 6 and Chlamydia pneumoniae as etiologic agents in multiple sclerosis — a critical review. Microbes Infect. (2002) 4:1327–1333.
   PubMed Web of Science ®Google Scholar
• ASCHERIO A, MUNGER KL, LENNETTE ET et al.: Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JA/VIA (2001) 286:3083–3088.
   Web of Science ®Google Scholar
• SIBLEY WA, BAMFORD CR, CLARK K:Clinical viral infections and multiplesclerosis. Lancet (1985) 1:1313–1315.
   PubMed Web of Science ®Google Scholar
• BERGSTROM T: Several options for antiviral treatment trials in multiple sclerosis-but which targets should be selected? Expert Opin. Pharmacother. (2000) 1:1087–1090.
   Google Scholar
• BECH E, LYCKE J, GADEBERG P et al.: A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS. Neurology (2002) 58:31–36.
   PubMed Web of Science ®Google Scholar
• SRIRAM S, STRATTON CW, YAO S et al.: Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. Ann. Neurol (1999) 46:6–14.
   PubMed Web of Science ®Google Scholar
• KRAMETTER D, NIEDERWIESER G, BERGHOLD A et al.: Chlamydia pneumoniae in multiple sclerosis: humoral immune responses in serum and cerebrospinal fluid and correlation with disease activity marker. Mult. Scler. (2001) 7:13–18.
   PubMed Web of Science ®Google Scholar
• GRIGGS RC: Chlamydia: conflict and controversy. Neurology(2001) 56:1130.
   PubMed Web of Science ®Google Scholar
• OWENS T, WEKERLE H, ANTEL J: Genetic models for CNS inflammation. Nat. Med. (2001) 7:161–166.
   PubMed Web of Science ®Google Scholar
• STEINMAN L, MARTIN R, BERNARD C, CONLON P, OKSENBERG JR: Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. Ann. Rev. Neurosci. (2002) 25:491–505.
   PubMed Web of Science ®Google Scholar
• ••Article summarising the most recent data in MS research that are achieved with novel technologies (including gene expression studies and proteomics) and how these approaches may help to unravel the most important mechanisms of tissue injury and response to therapy in MS, thus guiding the search for meaningful therapies.
   Google Scholar
• http://www.nationalmssociety.org National Multiple Sclerosis Society Homepage
   Google Scholar